Ownership
Public
Employees
~10
Therapeutic Areas
Infectious DiseasesOncology
Stage
Preclinical
Modalities
Protein therapeuticsPeptides

Decoy Therapeutics General Information

Developing peptide conjugate therapeutics using AI/ML platform. Lead asset is a pan-coronavirus antiviral approaching IND filing. Platform validated with ACE2-Fc showing broad neutralization against SARS-CoV-2 variants including Omicron.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

DCOY101
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Decoy Therapeutics's pipeline data

Book a demo

Key Partnerships

Johnson & Johnson (BLUE KNIGHT program), BARDA

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Decoy Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Decoy Therapeutics's complete valuation and funding history, request access »

Decoy Therapeutics Investors

Bill & Melinda Gates Foundation
Investor Type: Venture Capital
Holding: Minority
Massachusetts Life Sciences Seed Fund
Investor Type: Venture Capital
Holding: Minority
Google AI Startup Program
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »